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Abstract
Background: Conventionally, a nebulized short-acting b-2 agonist like salbutamol is often used as the reliever in
acute exacerbations of asthma. However, recent worldwide respiratory outbreaks discourage routine use of
nebulization. Previous studies have shown that combined budesonide/formoterol (Symbicort
®, AstraZeneca) is
effective as both a maintenance and reliever anti-asthmatic medication.
Methods: We performed a randomized, open-label study from March until August 2011 to compare the
bronchodilatory effects of Symbicort
® vs. nebulized salbutamol in acute exacerbation of mild to moderate
asthmatic attack in an emergency department. Initial objective parameters measured include the oxygen saturation,
peak expiratory flow rate (PEFR) and respiratory rate. During clinical reassessment, subjective parameters [i.e., Visual
Analog Scale (VAS) and 5-point Likert scale of breathlessness] and the second reading of the objective parameters
were measured. For the 5-point Likert scale, the patients were asked to describe their symptom relief as 1, much
worse; 2, a little worse; 3, no change; 4, a little better; 5, much better.
Results: Out of the total of 32 patients enrolled, 17 patients (53%) were randomized to receive nebulized
salbutamol and 15 (47%) to receive Symbicort
®. For both treatment arms, by using paired t- and Wilcoxon signed
rank tests, it was shown that there were statistically significant improvements in oxygen saturation, PEFR and
respiratory rate within the individual treatment groups (pre- vs. post-treatment). Comparing the effects of
Symbicort
® vs. nebulized salbutamol, the average improvement of oxygen saturation was 1% in both treatment
arms (p = 0.464), PEFR 78.67 l/min vs. 89.41 l/min, respectively (p = 0.507), and respiratory rate 2/min vs. 2/min (p =
0.890). For subjective evaluation, all patients reported improvement in the VAS (average 2.45 cm vs. 2.20 cm),
respectively (p = 0.765). All patients in both treatment arms reported either “a little better” or “much better” on the
5-point Likert scale, with none reporting “no change” or getting worse.
Conclusion: This study suggests that there is no statistical difference between using Symbicort
® vs. nebulized
salbutamol as the reliever for the first 15 min post-intervention.
Background
Defined as a chronic inflammatory airway disorder with
bronchial hyper-responsiveness to a variety of stimuli,
bronchial asthma is often punctuated with recurrent epi-
sodes of exacerbations with classical manifestations such
as wheezing, breathlessness, chest tightness, and noctur-
nal or early morning cough. These episodes are usually
associated with widespread but variable airflow obstruc-
tion within the lung that is often reversible either spon-
taneously or with treatment [1].
Conventionally, a nebulized short-acting b2 agonist
(SABA) like salbutamol is often used as the reliever in
acute exacerbations of asthma. However, the recent
worldwide respiratory outbreaks, such as the H1N1
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provided the original work is properly cited.pandemic flu (in 2009) and the severe acute respiratory
syndrome (SARS) outbreak (in 2002-2003), have dis-
couraged routine nebulization because of its apparent
association with air-borne infection spread [2].
Recent studies have shown that the similar bronchodi-
lator delivered via a metered-dose inhaler, combined
with a spacer, produces at least an equivalent improve-
ment in lung function as the same dose as delivered via
a nebulizer [3]. In fact, a previous study has found that
with MDI and a spacer, the dose that reaches the lungs
ranges from 15% to 20% of the total dose, whereas jet
nebulizers deposit only 8% to 10% of the total dose [4].
Nonetheless, despite the effectiveness of delivering a
bronchodilator via the metered dose route [3,4], nebu-
lized salbutamol is still very much preferred because of
its convenience [5]. Most patients when visiting an
emergency department expect to be given “something
more” than the metered dose inhalers that they had
been taking at home.
Formoterol is a long-acting b2-agonist (LABA) that
has a rapid onset bronchodilatory effect within 1-3 min
of inhalation [6]. Its rapid bronchodilatory effect is com-
parable with that of salbutamol, thus making it a suita-
ble alternative for the treatment of acute asthma and to
prevent exercise-induced bronchospasm [7]. In fact, for-
moterol has been shown to produce greater lung
improvements than salbutamol up to 4 h after adminis-
tration [8].
One of the reasons why formoterol exhibits a rapid
onset is because formoterol acts as a full agonist to
beta-2 receptors compared to salbutamol that acts as a
partial beta-2 agonist [6]. Furthermore, there are addi-
tional non-bronchodilatory beneficial effects of formo-
terol including the effect of reducing plasma exudation
by closing the gaps between endothelial cells, stabilizing
the mast cells and reducing neutrophilic recruitment,
and thus reducing the release of reactive oxygen species
through the activated neutrophils [9].
Combined budesonide/formoterol in a single inhaler
(Symbicort
®, AstraZeneca) has been shown to be effec-
tive as a maintenance and reliever anti-asthmatic medi-
cation [10]. In fact, this combination therapy has
recently been used in an effective novel approach called
Symbicort
® as Maintenance and Reliever Therapy
(SMART) approach [9,11]. SMART approach basically
means using Symbicort
® as a maintenance therapy twice
daily with additional puffs of the combination inhaler as
needed for symptom relief [9,11].
Methods
In this randomized, open-label study conducted from
March until August 2011, we compared the effects of
Symbicort
® (at the strength of 160/4.5 mcg per inhala-
tion) and nebulized salbutamol as the initial reliever in
acute exacerbation of mild to moderate bronchial
asthma in the Emergency Department, Hospital Univer-
siti Sains Malaysia (HUSM). We defined mild and mod-
erate asthmatic attack according to the guidelines
outlined in the Global Initiative of Asthma (GINA)
report on a global strategy for asthma management and
prevention. Adult patients aged 18 years old and above
who came to the Emergency Department of HUSM with
mild to moderate asthmatic attacks were included in the
study. We excluded patients referred from district hos-
pitals or other health facilities (who may have been
given reliever treatment prior to arrival), pregnancy,
patients who are already started on any LABA medica-
tions as well as patients with persistent poor inhalational
techniques despite being taught the proper technique in
the Emergency Department. This study was approved by
the hospital’s ethics and research committee.
Patients who consented to participate in this study
were randomized to receive either two puffs of Symbi-
cort
® or nebulized salbutamol. Patients randomized to
receive Symbicort
® were given proper instruction on the
inhalational technique using the dummy turbuhaler
devices supplied by AstraZeneca (Malaysia). Initial
objective parameters obtained include the respiratory
rate, oxygen saturation and peak expiratory flow rate
(PEFR). The patients were then reassessed after 15 min.
Objective and subjective variables related to the study
were then recorded. Subjective parameters related to
patients’ perception of symptomatic relief were assessed
using the Visual Analog Scale (VAS) and the 5-point
Likert scale of breathlessness.
VAS is a widely used measurement scale for many
symptoms including pain and breathlessness at a specific
point in time. We recorded two readings (pre- and post-
intervention) on a 10-cm scale with the spectrum of
completely asymptomatic on one end and the most
severe asthmatic symptoms ever experienced on the
other end. In this study, we adopted the finding from a
previous study where a change of 2.2 cm is defined as
the minimal clinically significant improvement of
asthma management in the emergency departments [12].
For the 5-point Likert scale, during reassessment of
the patient 15 min after giving the allocated treatment,
the patients were asked to describe their symptom relief
on a 5-point scale of 1, much worse; 2, a little worse; 3,
no change; 4, a little better; 5, much better
Subsequent management after the initial treatment
and the decision for patient disposition were decided
according to the discretion of the treating doctor based
on the clinical improvement of the patient concerned.
Patients who need admission are admitted accordingly,
and patients with the nebulized salbutamol deemed fit
for discharge are discharged with inhaled budesonide
(Pulmicort
® 100 mcg per inhalation, AstraZeneca) at a
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tamol on an as-needed basis for 30 days. Patients in the
Symbicort
® arm are discharged with two inhalations of
Symbicort
® as maintenance besides additional doses on
an as-needed basis for up to eight doses for 30 days. All
patients are given an appointment to attend a follow-up
visit after 30 days to assess symptom progression.
All data were analyzed using Statistical Package for
Social Sciences (SPSS
®) Statistics software version
19.0.0. For categorical analysis, chi-square and Fisher’s
exact tests were used. For numerical analysis, dependent
and independent Student’s t-tests were used for para-
metric data, and Wilcoxon’s signed rank test and Mann-
Whitney test were used for nonparametric dependent
and independent data, respectively. The block randomi-
zation process used in this study was generated using
software available from the web [13].
Results
O u to ft h et o t a lo f3 2p a t i e n t se n r o l l e d ,1 7( 5 3 % )w e r e
randomized to receive nebulized salbutamol and 15
(47%) to receive Symbicort
® (Table 1). None of the
patients required admission, and none of them required
additional doses of relievers.
For patients within the Symbicort
® arm, by using the
paired t-test for PEFR (parametric) and Wilcoxon signed
rank test for respiratory rate and SaO2 (non-parametric),
it was shown that there were statistically significant
improvements in SaO2 and PEFR, and reduction in the
respiratory rate (improvement of tachypnea) in patients
after using Symbicort
® tubuhaler. Similar statistically
significant changes were demonstrated in the nebulized
salbutamol arm (Table 2).
Arguably, although the statistically significant changes in
this study may not be noticeable clinically, yet, on subjec-
tive assessment, regardless of the type of intervention, 18
out of 32 (56%) patients reported being “a little better” on
the 5-point Likert scale, and another 14 out of the 32
(44%) reported a “much better” response. All patients
reported improvement in the VAS with the mean VAS of
2.45 cm and 2.20 cm in the Symbicort
® and nebulized sal-
butamol arms, respectively (Table 1).
Specifically, in the Symbicort
® arm, on the 5-point Likert
scale, nine patients (60%) said they felt “a little better,” and
another six patients (40%) said they felt “much better.”
Similarly, for the nebulized salbutamol arm, nine patients
(52.9%) felt “a little better,” and eight patients (47.1%) felt
“much better” on the 5-point Likert scale. None of the
patients in either arm reported feeling “no change,”“ al i t t l e
worse” or “much worse” after interventions (Table 1). Inci-
dentally, as all patients responded as being either “a little
better” or “much better,” we performed a post-hoc analysis
using the chi-square test to compare the subjective
improvement of Symbicort
® versus nebulized salbutamol,
and we found that there is no statistically significant differ-
ence between these two treatments (p = 0.688).
Discussion
In this study, both nebulized salbutamol and Symbicort
®
demonstrated objective and subjective clinical
Table 1 Baseline characteristics and between-group analysis
Symbicort
® Nebulized
salbutamol
p value
Total no. of patients (n,% ) 1 5 1 7
Mean age in years (SD) 36.47 (16.26) 42.59 (15.86)
Gender
Male 59
Female 10 8
Objective parameters
Mean PEFR improvement (SD) in l/min Δ 78.67(44.86) Δ 89.41(45.48) 0.507
Median value (IQR) of improvement of SaO2 in % Δ 1 (1) Δ 2 (1) 0.464
Median value (IQR) of reduction in respiratory rate (per min) ∇ 2 (2)/min ∇ (3)/min 0.890
Subjective parameters
5-point Likert scale: - -
1–much worse - -
2–a little worse - -
3–no change - -
4–a little better 9 (60%) 9 (52.9%)
5–much better 6 (40%) 8 (47.1%)
VAS changes in cm (SD) 2.45 (1.31) 2.20 (2.10) 0.765
Note:
Δ denotes an increase in value; ∇ denotes a decrease in value
IQR means interquartile range
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cally designed to show non-inferiority of one drug over
another, our study does suggest that Symbicort
® is as
effective as nebulized salbutamol when used as a reliever
in the emergency department for the first 15 min, which
is consistent with the findings from another study that
Symbicort
® is as effective as salbutamol in metered-dose
inhalation [14].
Even though at this stage it is premature to state
whether Symbicort
® c a no rs h o u l db eu s e da sa na l t e r -
native reliever in acute asthmatic attacks, nonetheless,
we demonstrated that both Symbicort
® and salbutamol
offer similar improvement in objective and subjective
assessments, and that there is no difference between the
two.
This study is severely limited because of the inherent
weaknesses of its methodology. It is an open-label, non-
blinded trial involving a small sample size of 32 patients.
Furthermore, in this study, the patient’s comorbidities,
duration of asthma and risk factors such as smoking sta-
tus were not taken into consideration. However, this
study may pave the way for larger studies in the future
to study the beneficial effects of Symbicort
® beyond the
first 15 min and whether it can be used as an alternative
reliever. A better alternative methodology would be to
add a placebo inhaler for patients in the nebulized sal-
butamol arm and a placebo nebulization (e.g., saline) for
the Symbicort
® arm. In this way, the confounding bias
due to the different drug delivery systems could be
minimized.
Furthermore, one of the common problems in long-
term asthma care is poor adherence to inhaled corticos-
teroid (ICS) maintenance therapy, resulting in under-
treatment of the underlying airway inflammation. This
is often because patients do not understand the differ-
ence between maintenance and reliever medications as
well as the importance of regular ICS use [15,16]. As a
result, many patients tend to over-rely on short-acting
b-2 agonist medications for quick relief of symptoms at
the expense of omitting their ICS therapy, thus lowering
anti-inflammatory protection and increasing the propen-
sity for the development of severe and potentially life-
threatening exacerbations [17]. If an alternative agent
that combines both reliever and maintenance medica-
tions could be used, this would simplify treatment and
provide a more convenient and effective way in which
to deliver medications to the endobronchial tree.
Conclusion
In conclusion, this study shows that when Symbicort
® is
used as a reliever in acute mild to moderate asthmatic
attacks, it does not demonstrate any statistical difference
when compared to nebulized salbutamol in the first 15
min. Ultimately, with the recent development of many
respiratory outbreaks, we hope that the findings in this
study can translate into helping to minimize the occur-
rence of unnecessary nebulizations by using an alterna-
tive agent that is not only equally effective, but also well
accepted by the patients.
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